CD19 and neoplasm: CD19 was selected as a CAR target in part for its limited expression in normal cells (5), which is largely confined to B cells and thus exposes CD19 CAR T cell recipients to B-cell aplasia, a clinically manageable on-target/off-tumor toxicity.